Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1653 1655
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17996966 | NOVEL T-CELL SPECIFICITIES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18148886 | TARGETING BCL11A ENHANCER FUNCTIONAL REGIONS FOR FETAL HEMOGLOBIN REINDUCTION | Non-Final OA | Massachusetts Institute of Technology |
| 17618774 | RECOMBINANT AD35 VECTORS AND RELATED GENE THERAPY IMPROVEMENTS | Final Rejection | University of Washington |
| 18178675 | Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing | Non-Final OA | The General Hospital Corporation |
| 18297323 | MOTOR NEURON-SPECIFIC EXPRESSION VECTORS | Non-Final OA | Salk Institute for Biological Studies |
| 18331851 | NOVEL PEPTIDE, COMPOSITIONS AND METHOD FOR DELIVERY OF AGENTS INTO CELLS AND TISSUES | Non-Final OA | Trustees of Tufts College |
| 17244079 | FOWL ADENOVIRUS 9 (FADV-9) VECTOR SYSTEM AND ASSOCIATED METHODS | Non-Final OA | University of Guelph |
| 18052735 | CODON OPTIMIZED REP1 GENES AND USES THEREOF | Non-Final OA | 4D MOLECULAR THERAPEUTICS INC. |
| 17640725 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR NON-ALCOHOLIC FATTY LIVER, CONTAINING DENTAL TISSUE-DERIVED MULTIPOTENT STEM CELLS | Non-Final OA | STEMCENTRIC CO., LTD. |
| 15734203 | DIVERSE ANTIGEN BINDING DOMAINS, NOVEL PLATFORMS AND OTHER ENHANCEMENTS FOR CELLULAR THERAPY | Final Rejection | Angeles Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy